Goodwin-Led Cabaletta Bio Launches $87M IPO
Cabaletta Bio, which develops treatments for autoimmune diseases, said Wednesday it is planning to raise $87 million in its Goodwin Procter-led initial public offering if the shares are priced at midpoint....To view the full article, register now.
Already a subscriber? Click here to view full article